Crispr Therapeutics (NASDAQ:CRSP) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Friday, BidAskClub reports.

Several other analysts have also recently issued reports on CRSP. Zacks Investment Research cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. ValuEngine raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Canaccord Genuity lifted their price objective on Crispr Therapeutics from $72.00 to $80.00 and gave the company a “positive” rating in a research report on Wednesday, November 20th. Goldman Sachs Group lifted their price objective on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Finally, William Blair raised Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have issued a buy rating to the stock. Crispr Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $69.54.

Shares of NASDAQ CRSP traded down $0.67 during trading hours on Friday, hitting $65.36. The company’s stock had a trading volume of 739,581 shares, compared to its average volume of 712,269. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The stock has a market cap of $3.62 billion, a price-to-earnings ratio of -19.00 and a beta of 3.31. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $74.00. The business has a 50-day simple moving average of $58.93 and a 200-day simple moving average of $48.44.

Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. On average, equities research analysts forecast that Crispr Therapeutics will post 0.65 EPS for the current year.

In other news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares in the company, valued at $412,500. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 56,118 shares of company stock worth $3,620,760. Insiders own 21.40% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of CRSP. BNP Paribas Arbitrage SA bought a new stake in shares of Crispr Therapeutics in the 2nd quarter worth approximately $41,000. Aperio Group LLC bought a new stake in shares of Crispr Therapeutics in the 2nd quarter worth approximately $153,000. Swiss National Bank boosted its position in shares of Crispr Therapeutics by 28.6% in the 2nd quarter. Swiss National Bank now owns 48,600 shares of the company’s stock worth $2,289,000 after purchasing an additional 10,800 shares in the last quarter. National Asset Management Inc. bought a new stake in shares of Crispr Therapeutics in the 2nd quarter worth approximately $362,000. Finally, Wells Fargo & Company MN boosted its position in shares of Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares in the last quarter. 49.82% of the stock is currently owned by hedge funds and other institutional investors.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: Understanding Specialty Certificates of Deposit

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.




Source link